In this interview, John W. Davis, MD, discusses the advantages and limitations of focal therapy, the ideal candidate, and what current guidelines say about its use.
J. Brantley Thrasher, MD
“Active surveillance continues to gain traction as a management strategy for low-risk prostate cancer in the United States. However, barriers still exist and challenges remain for both the treating urologist and the patient,” writes J. Brantley Thrasher, MD.
In this interview, E. Jason Abel, MD, discusses biopsy’s role in small and large renal masses, associated risks, and when patients can be safely observed.
In this interview, Arie Belldegrun, MD, discusses the benefits of cancer immunotherapy, the importance of a multidisciplinary treatment approach, and what the future holds for this treatment.
The AUA is challenged with staying fair and relevant to all urologists under the "big tent," even though academic-employed urologists, non-academic-employed urologists, those in private practice, and those in large group practices may have different priorities and problems.
PSA is performing appropriately, allowing us to diagnose prostate cancers at an earlier stage and grade and allowing treatment while cure is still possible.
The study adds to a growing body of literature now suggesting that ADT in combination with EBRT is not indicated for the low-risk patient.
Further analysis of completed studies, along with the completion of ongoing trials, will hopefully clarify the optimal length of adjuvant ADT
We must increase the number of, and accrual to, clinical trials. The best way is in the setting of multidisciplinary clinics.